新和新兴的治疗一般性性牛皮:关注IL-36受体抑制剂
João Vilaça1, Orhan Yilmaz2, Tiago Torres1,3
1Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal.
Pharmaceutics
|July 27, 2024
概括
针对IL-36通路的新疗法为泛性皮质银病 (GPP) 患者提供了希望. 斯佩索利马布和伊姆西多利马布显示出有前途的安全性和有效性,可能成为这种严重皮肤疾病的首要选择.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泛性皮囊性牛皮 (GPP) 是一种罕见的,严重的皮肤疾病,对生活质量产生重大影响.
- 以前的GPP治疗方法缺乏特异性,并且经常引起副作用,突出了需要更安全,更有效的选择.
- 互白素-36 (IL-36) 途径在GPP的发病过程中具有关键作用,这表明它是治疗标.
研究的目的:
- 综述和总结最近在GPP治疗方面的进展.
- 探索针对IL-36通路的新型治疗剂.
- 评估新兴GPP治疗方法的安全性和有效性.
主要方法:
- 关于GPP治疗的科学出版物的文献综述.
- 对IL-36通路抑制剂的临床试验数据的分析.
- 目前关于spesolimab和imsidolimab的研究总结.
主要成果:
- 斯佩索利马布和伊姆西多利马布向IL-36受体 (IL-36R).
- 第1期和第2期临床试验表明,这些生物制剂的安全性和有效性是有希望的.
- IL-36受体抑制剂显示出作为GPP的主要治疗方法的潜力.
结论:
- IL-36受体抑制剂代表了GPP管理的重大进步.
- 与以前的治疗方法相比,这些新型疗法提供了更好的疗效和安全性.
- 预计进一步的研究和临床应用将使这些药物成为领先的GPP治疗方法.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
T Cell Types and Functions
967
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
967
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Drugs Used in Lower Respiratory Disorders: Overview
386
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
386


